Gain Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 26, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 26, 2026

GANX$1.09+5.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets


· · · December 31, · · December 31,
· · · 2025 · · 2024
Assets · · · ·
Current assets: · · · ·
Cash and cash equivalents	$20,837,628	$10,385,863
Tax credits	179,701	271,079
Prepaid expenses and other current assets	1,219,809	945,536
Total current assets	22,237,138	11,602,478

Noncurrent assets:
Property and equipment, net	74,916	103,619
Internal-use software, net	102,837	134,268
Operating lease right-of-use assets	334,090	219,715
Restricted cash	36,296	31,695
Long-term deposits and other noncurrent assets	33,698	32,109
Total noncurrent assets	581,837	521,406
Total assets	$22,818,975	$12,123,884

Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$825,027	$946,259
Operating lease liabilities - current	119,876	160,913
Other current liabilities	2,306,624	2,441,761
Deferred grant income - current	—	252,211
Loans - current	100,869	110,177
Total current liabilities	3,352,396	3,911,321

Noncurrent liabilities:
Defined benefit pension plan	390,509	443,623
Operating lease liabilities - noncurrent	211,238	53,598
Deferred grant income - noncurrent	—	47,441
Loans - noncurrent	300,084	328,327
Total noncurrent liabilities	901,831	872,989
Total liabilities	$4,254,227	$4,784,310

Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; nil shares issued and outstanding as of December 31, 2025 and 2024	$—	$—
Common stock, $0.0001 par value: 100,000,000 shares authorized; 42,073,807 and 27,132,588 shares issued and outstanding as of December 31, 2025 and 2024, respectively	4,209	2,713
Additional paid-in capital	119,139,677	88,779,318
Accumulated other comprehensive income (loss)	776,869	(247,549)
Accumulated deficit	(81,194,908)	(60,783,717)
Loss of the period	(20,161,099)	(20,411,191)
Total stockholders’ equity	18,564,748	7,339,574
Total liabilities and stockholders’ equity	$22,818,975	$12,123,884

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.